The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety
of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250
mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the
knee, in comparison with placebo and Oxycodone Controlled Release (CR).
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.